How does AST data support antibiotic de-escalation in stewardship?

How does AST data support antibiotic de-escalation in stewardship?

• A. By identifying susceptible narrow-spectrum agents appropriate for the pathogen, enabling targeted therapy and avoiding broad-spectrum use.
• B. By increasing broad-spectrum coverage to prevent resistance.
• C. By shortening therapy duration regardless of susceptibility.
• D. By reporting resistance genes only.

Answer: (B)

AST data supports de-escalation by revealing which drugs are actually active against the pathogen, so clinicians can switch from broad, empiric therapy to a narrow-spectrum agent with proven effectiveness. When the lab shows the organism is susceptible to a specific narrow-spectrum antibiotic, therapy can be targeted to that drug, reducing unnecessary broad-spectrum exposure and its associated risks—adverse effects, higher cost, and, importantly, the acceleration of resistance. The susceptibility results (often accompanied by MICs) guide not only which drug to use but also the appropriate dosing to achieve effective concentrations. Relying on broader coverage to prevent resistance runs counter to stewardship goals, while shortening therapy should be based on both susceptibility and clinical context rather than applied automatically. Reports of resistance genes can be informative but don’t replace actual phenotypic susceptibility, which is essential for choosing a precise, narrow agent.

AST data supports de-escalation by revealing which drugs are actually active against the pathogen, so clinicians can switch from broad, empiric therapy to a narrow-spectrum agent with proven effectiveness. When the lab shows the organism is susceptible to a specific narrow-spectrum antibiotic, therapy can be targeted to that drug, reducing unnecessary broad-spectrum exposure and its associated risks—adverse effects, higher cost, and, importantly, the acceleration of resistance. The susceptibility results (often accompanied by MICs) guide not only which drug to use but also the appropriate dosing to achieve effective concentrations. Relying on broader coverage to prevent resistance runs counter to stewardship goals, while shortening therapy should be based on both susceptibility and clinical context rather than applied automatically. Reports of resistance genes can be informative but don’t replace actual phenotypic susceptibility, which is essential for choosing a precise, narrow agent.